anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
== Awards and honors == Stas Medal of the Belgian Chemical Society (1962) Fellow of the American Academy of Arts and Sciences (1966) Fritz Pregl Medal of the Austrian Microchemical Society (1977) NASA Exceptional Scientific Achievement Medal (1977) Guggenheim Fellow (1983) Field and Franklin Award in Applied Mass Spectrometry from the American Chemical Society (1986) ACS Analytical Chemistry Award from the American Chemical Society (2001) Thomson Medal from the International Mass Spectrometry Foundation (1991) Pehr Edman Award (1992) Member of the National Academy of Sciences (1993) Beckman-ABRF Award from the Association of Biomolecular Resource Facilities (1995) Benjamin Franklin Medal in Chemistry from the Franklin Institute (2007)
== Legal status == DNP is banned for human consumption in many countries. Because it has some legitimate uses, in many jurisdictions, DNP is legal to sell, but not for human consumption. DNP has been banned by the World Anti-Doping Association since 2015. Petróczi et al. recommend against campaigns informing people of the risks of DNP because it could increase use of the drug. However, Sousa et al. argue that publicity campaigns in the United Kingdom in the early and mid-2010s reduced DNP usage. In 2015, Interpol and the World Anti-Doping Agency released an orange notice warning of the dangers of DNP. In 1941, the Eastman Kodak Company, a bulk distributor of DNP, was investigated after some of its product was found in illegal diet pills. Nicholas Bachynsky, a Texas physician, provided the drug to patients under the name "Mitcal". He was convicted of violating drug laws in 1986, but continued to work with DNP and was additionally convicted of fraud in 2008. In 2018, a seller in the United Kingdom was convicted of manslaughter for selling DNP for human consumption. The conviction was sent to retrial in 2020 by the English Court of Appeal, where the seller was, once again, convicted of gross negligence manslaughter. The UK government reclassified DNP as a regulated poison with effect from October 2023.
11 November An investigation by the Independent Police Conduct Authority concludes that several senior New Zealand Police executives including former Police Commissioner Andrew Coster had covered up allegations of serious offending lodged by a police employee against former Deputy Police Commissioner Jevon McSkimming. The government proposes the transfer of gun licensing responsibilities from the police to an independent Firearms Safety Authority. The Otago Regional Council extends OceanaGold's mining consent for its Macraes gold mine for another five years. 13 November – ACT leader and Deputy Prime Minister David Seymour's controversial Regulatory Standards Bill passes its third reading in Parliament, becoming law. 14 November: The New Zealand Government allocates NZ$2 million to the Dunedin Tunnels Trail cyclewear connecting Dunedin and Mosgiel. Several schools and early childhood centres close after the Ministry of Business, Innovation and Employment (MBIE) issues a recall notice for two coloured sands products over concerns about asbestos contamination. 17 November – The Supreme Court of New Zealand upholds a 2024 Court of Appeal decision that Uber drivers were employees rather than contractors. 18 November: Taumata Arowai, the national water regulator, takes control of the Northland town of Kāeo's drinking water supply from private contractor, Wai Care Environmental Consultants. The town had been under a boil water notice for ten years and lacked running water.
Excitotoxicity Cell death caused by excessive stimulation by neurotransmitters such as glutamate, leading to calcium overload and neuronal damage. It is implicated in stroke and neurodegenerative diseases. Executive function A set of cognitive processes including working memory, flexible thinking, and self-control. Primarily associated with the prefrontal cortex. Exocytosis The process by which vesicles release their contents outside the cell. In neurons, it refers to the release of neurotransmitters into the synaptic cleft. Extracellular matrix A network of proteins and molecules outside cells
Sources: en.wikipedia.org
Radioisotopes of caesium require special precautions: the improper handling of caesium-137 gamma ray sources can lead to release of this radioisotope and radiation injuries. Perhaps the best-known case is the Goiânia accident of 1987, in which an improperly-disposed-of radiation therapy system from an abandoned clinic in the city of Goiânia, Brazil, was scavenged from a junkyard, and the glowing caesium salt sold to curious, uneducated buyers. This led to four deaths and serious injuries from radiation exposure. Together with caesium-134, iodine-131, and strontium-90, caesium-137 was among the isotopes distributed by the Chernobyl disaster which constitute the greatest risk to health. Radioisotopes of francium would presumably be dangerous as well due to their high decay energy and short half-life, but none have been produced in large enough amounts to pose any serious risk.
Increases in myostatin levels during chronic heart failure have been shown to cause cardiac cachexia. Systemic inhibition of cardiac myostatin with the JA-16 antibody maintains overall muscle weight in experimental models with pre-existing heart failure. Myostatin also alters excitation-contraction (EC) coupling within the heart. A reduction in cardiac myostatin induces eccentric hypertrophy of the heart, and increases its sensitivity to beta-adrenergic stimuli by enhancing Ca2+ release from the SR during EC coupling. Also, phospholamban phosphorylation is increased in myostatin-knockout mice, leading to an increase in Ca2+ release into the cytosol during systole. Therefore, minimizing cardiac myostatin may improve cardiac output.
=== Relationship with Japan === Japan was one of the few regimes to support Noriega at a time when he was under intense pressure from Reagan and found himself isolated. Japan was then Panama's second largest trading partner and had invested $8.8 billion in its economy. Japan had established Panama as the center of its expansion in Latin America. "There was a peak of relations with Japan in which they saw the importance of the Pacific in relation to the Atlantic and the need to expand the Canal," Noriega said in a 2017 interview. In June 1988, Tokyo gave its official backing to the Panamanian military government.
=== Homozygous Hb Lepore === Those homozygous (Hb LeporeLepore; a very rare situation) or compound heterozygous (Hb Lepore-Β-thalassaemia) might suffer from a severe anaemia. They should be managed in a comprehensive multi-disciplinary program of care. Management includes a regular course of blood transfusions, although the clinical severity in compound (double) heterozygotes can range from minor to major, depending on the combination of genes that have caused the condition.
On 9 January 2024, the Kata'ib Hezbollah spokesperson Jafar al-Husseini warned that the Islamic Resistance in Iraq would help Hezbollah fight Israel if war erupted between the two sides. This statement was a few weeks after the Islamic Resistance in Iraq claimed responsibility for a drone attack on a Karish rig which Lebanon claims to hold sovereignty to. On 23 June 2024, the spokesperson to Kata'ib Sayyid al-Shuhada Kadhem al-Fartousi said the brigade will join Hezbollah's side if Israel decides to launch a full-blown war in Lebanon. On 24 June 2024, Qais al-Khazali, the leader of Asa'ib Ahl al-Haq, stated in a televised speech that if the U.S. continued to support Israel in expanding the war to Lebanon and Hezbollah, the group would begin to attack US interests in Iraq and the Middle East.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.